Pharsight

Combivent Respimat is owned by Boehringer Ingelheim.

Combivent Respimat contains Albuterol Sulfate; Ipratropium Bromide.

Combivent Respimat has a total of 6 drug patents out of which 0 drug patents have expired.

Combivent Respimat was authorised for market use on 07 October, 2011.

Combivent Respimat is available in spray, metered;inhalation dosage forms.

The generics of Combivent Respimat are possible to be released after 16 October, 2030.

Application	Filing Date	Opposition Party	Legal Status
EP2004006768W	2012-04-12	Knorr-Bremse Systeme für Nutzfahrzeuge GmbH	Revoked

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7284474	BOEHRINGER INGELHEIM	Piston-pumping system having o-ring seal properties	Aug, 2024 (1 year, 2 months from now)
US7896264	BOEHRINGER INGELHEIM	Microstructured high pressure nozzle with built-in filter function	May, 2025 (1 year, 11 months from now)
US7396341	BOEHRINGER INGELHEIM	Blocking device for a locking stressing mechanism having a spring-actuated output drive device	Oct, 2026 (3 years from now)
US9027967	BOEHRINGER INGELHEIM	Device for clamping a fluidic component	Mar, 2027 (3 years from now)
US7837235	BOEHRINGER INGELHEIM	Device for clamping a fluidic component	Mar, 2028 (4 years from now)
US8733341	BOEHRINGER INGELHEIM	Atomizer and method of atomizing fluid with a nozzle rinsing mechanism	Oct, 2030 (7 years from now)